These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

206 related items for PubMed ID: 22948739

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Volume-based metabolic tumor response to neoadjuvant chemotherapy is associated with an increased risk of recurrence in breast cancer.
    Hyun SH, Ahn HK, Park YH, Im YH, Kil WH, Lee JE, Nam SJ, Cho EY, Choi JY.
    Radiology; 2015 Apr; 275(1):235-44. PubMed ID: 25496075
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. FDG PET/CT during neoadjuvant chemotherapy may predict response in ER-positive/HER2-negative and triple negative, but not in HER2-positive breast cancer.
    Koolen BB, Pengel KE, Wesseling J, Vogel WV, Vrancken Peeters MJ, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Valdés Olmos RA.
    Breast; 2013 Oct; 22(5):691-7. PubMed ID: 23414930
    [Abstract] [Full Text] [Related]

  • 6. Prognostic Impact of [18F] FDG-PET in operable breast cancer treated with neoadjuvant chemotherapy.
    Jung SY, Kim SK, Nam BH, Min SY, Lee SJ, Park C, Kwon Y, Kim EA, Ko KL, Park IH, Lee KS, Shin KH, Lee S, Kim SW, Kang HS, Ro J.
    Ann Surg Oncol; 2010 Jan; 17(1):247-53. PubMed ID: 19777177
    [Abstract] [Full Text] [Related]

  • 7. Early assessment of axillary response with ¹⁸F-FDG PET/CT during neoadjuvant chemotherapy in stage II-III breast cancer: implications for surgical management of the axilla.
    Koolen BB, Valdés Olmos RA, Wesseling J, Vogel WV, Vincent AD, Gilhuijs KG, Rodenhuis S, Rutgers EJ, Vrancken Peeters MJ.
    Ann Surg Oncol; 2013 Jul; 20(7):2227-35. PubMed ID: 23456316
    [Abstract] [Full Text] [Related]

  • 8. 18F-FDG semi-quantitative parameters and biological prognostic factors in locally advanced breast cancer.
    García Vicente AM, Soriano Castrejón A, Relea Calatayud F, Muñoz Madero V, Molina Garrido MJ, León Martín AA, Cordero García JM, Pilkington Woll JP, Chacón López-Muñiz I, Palomar Muñoz A.
    Rev Esp Med Nucl Imagen Mol; 2012 Jul; 31(6):308-14. PubMed ID: 23084013
    [Abstract] [Full Text] [Related]

  • 9. Predictive value of PET-CT for pathological response in stages II and III breast cancer patients following neoadjuvant chemotherapy with docetaxel.
    García García-Esquinas MA, Arrazola García J, García-Sáenz JA, Furió-Bacete V, Fuentes Ferrer ME, Ortega Candil A, Cabrera Martín MN, Carreras Delgado JL.
    Rev Esp Med Nucl Imagen Mol; 2014 Jul; 33(1):14-21. PubMed ID: 23809513
    [Abstract] [Full Text] [Related]

  • 10. [Value of fused 18F-FDG PET/CT images in predicting efficacy of neoadjuvant chemotherapy on breast cancer].
    Li D, Chen JH, Wang J, Ling R, Yao Q, Wang L.
    Ai Zheng; 2007 Aug; 26(8):900-4. PubMed ID: 17697556
    [Abstract] [Full Text] [Related]

  • 11. Predictive value of FDG PET/CT for pathologic axillary node involvement after neoadjuvant chemotherapy.
    Keam B, Im SA, Koh Y, Han SW, Oh DY, Cho N, Kim JH, Han W, Kang KW, Moon WK, Kim TY, Park IA, Noh DY, Chung JK, Bang YJ.
    Breast Cancer; 2013 Apr; 20(2):167-73. PubMed ID: 22311581
    [Abstract] [Full Text] [Related]

  • 12. Can FDG-PET/CT predict early response to neoadjuvant chemotherapy in breast cancer?
    Andrade WP, Lima EN, Osório CA, do Socorro Maciel M, Baiocchi G, Bitencourt AG, Fanelli MF, Damascena AS, Soares FA.
    Eur J Surg Oncol; 2013 Dec; 39(12):1358-63. PubMed ID: 24120422
    [Abstract] [Full Text] [Related]

  • 13. HER2-positive breast cancer: ¹⁸F-FDG PET for early prediction of response to trastuzumab plus taxane-based neoadjuvant chemotherapy.
    Humbert O, Cochet A, Riedinger JM, Berriolo-Riedinger A, Arnould L, Coudert B, Desmoulins I, Toubeau M, Dygai-Cochet I, Guiu S, Coutant C, Fumoleau P, Brunotte F.
    Eur J Nucl Med Mol Imaging; 2014 Aug; 41(8):1525-33. PubMed ID: 24647576
    [Abstract] [Full Text] [Related]

  • 14. Baseline Tumor 18F-FDG Uptake and Modifications After 2 Cycles of Neoadjuvant Chemotherapy Are Prognostic of Outcome in ER+/HER2- Breast Cancer.
    Groheux D, Sanna A, Majdoub M, de Cremoux P, Giacchetti S, Teixeira L, Espié M, Merlet P, de Roquancourt A, Visvikis D, Hatt M, Resche-Rigon M, Hindié E.
    J Nucl Med; 2015 Jun; 56(6):824-31. PubMed ID: 25883123
    [Abstract] [Full Text] [Related]

  • 15. Evaluation of the Response to Breast Cancer Neoadjuvant Chemotherapy Using 18F-FDG Positron Emission Mammography Compared With Whole-Body 18F-FDG PET: A Prospective Observational Study.
    Noritake M, Narui K, Kaneta T, Sugae S, Sakamaki K, Inoue T, Ishikawa T.
    Clin Nucl Med; 2017 Mar; 42(3):169-175. PubMed ID: 28072617
    [Abstract] [Full Text] [Related]

  • 16. 18F-FDG uptake by metastatic axillary lymph nodes on pretreatment PET/CT as a prognostic factor for recurrence in patients with invasive ductal breast cancer.
    Song BI, Lee SW, Jeong SY, Chae YS, Lee WK, Ahn BC, Lee J.
    J Nucl Med; 2012 Sep; 53(9):1337-44. PubMed ID: 22870824
    [Abstract] [Full Text] [Related]

  • 17. Estrogen receptor-positive/human epidermal growth factor receptor 2-negative breast tumors: early prediction of chemosensitivity with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography during neoadjuvant chemotherapy.
    Groheux D, Hatt M, Hindié E, Giacchetti S, de Cremoux P, Lehmann-Che J, Martineau A, Marty M, Cuvier C, Cheze-Le Rest C, de Roquancourt A, Visvikis D, Espié M.
    Cancer; 2013 Jun 01; 119(11):1960-8. PubMed ID: 23504954
    [Abstract] [Full Text] [Related]

  • 18. Role of 18F-PET/CT in Predicting Prognosis of Patients With Breast Cancer After Neoadjuvant Chemotherapy.
    Akimoto E, Kadoya T, Kajitani K, Emi A, Shigematsu H, Ohara M, Masumoto N, Okada M.
    Clin Breast Cancer; 2018 Feb 01; 18(1):45-52. PubMed ID: 28993056
    [Abstract] [Full Text] [Related]

  • 19. Determinants of response to neoadjuvant chemotherapy for esophageal cancer using 18F-fluorodeoxiglucose positron emission tomography (18F-FDG-PET).
    Miyata H, Yamasaki M, Takahashi T, Murakami K, Tanaka K, Yukinori K, Nakajima K, Takiguchi S, Morii E, Hatazawa J, Mori M, Doki Y.
    Ann Surg Oncol; 2014 Feb 01; 21(2):575-82. PubMed ID: 24201746
    [Abstract] [Full Text] [Related]

  • 20. 18F-FDG PET/CT to Predict Response to Neoadjuvant Chemotherapy and Prognosis in Inflammatory Breast Cancer.
    Champion L, Lerebours F, Alberini JL, Fourme E, Gontier E, Bertrand F, Wartski M.
    J Nucl Med; 2015 Sep 01; 56(9):1315-21. PubMed ID: 26159587
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.